Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-Cancer Therapeutics

The traditional anti-convulsant drug Valproic Acid (VPA) has been found to be involved in suppressing cancer progression while modulating various cancer-associated signaling pathways. In particular, VPA acts as either a Histone Deacetylase (HDAC) inhibitor or a Notch signaling activator in suppressing tumor growth. VPA is less toxic, and by itself, has limited anti-tumor effects. Thus, VPA has been used as an adjuvant in combination with a variety of other anti-cancer agents for many types of cancers. These combination strategies display potential applications in cancer treatments. In particular, VPA could up-regulate certain G Protein-Coupled Receptors (GPCRs) in some cancer cells. Some of these GPCRs are highly expressed naturally in many cancer cells and these characteristics have been applied towards novel enhanced combination therapeutics with VPA and specific receptor-targeted cytotoxic peptide-drug conjugates. *Corresponding author: Lichun Sun, Professor, Department of Medicine, Peptide Research Laboratories, Tulane Health Sciences Center, New Orleans, LA 701122699, USA, Tel: 504-988-1179; Fax: 504-988-3586; E-mail: [email protected] Received January 02, 2014; Accepted January 22, 2014; Published January 27, 2014 Citation: Sun L, Coy DH (2014) Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-Cancer Therapeutics. Mod Chem appl 2: 118. doi:10.4172/2329-6798.1000118 Copyright: © 2014 Sun L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.